BNTX BioNTech
- 92.960
- +0.900+0.98%
BioNTech News
Novavax Hits a 52-week High as Sanofi Deal Prompts J.P. Morgan Upgrade
Analysts Conflicted on These Healthcare Names: BioNTech SE (BNTX), Xenon (XENE) and BioLife Solutions (BLFS)
Novavax Gets $1.4 Billion Deal With Sanofi. The Stock Jumps.
The two companies will also work on a shot that combines Covid-19 and flu vaccines.
The coronavirus hasn't disappeared yet! A new “FlIRt variant family” is spreading in the US...
① According to CDC data, the main variant of transmission in the US today is the “FlIRT” family, led by KP.2; ② KP.2 accounts for 25%; ③ medical experts warn that fLiRT has a more obvious transmission advantage and may trigger a new wave of COVID-19.
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
European equities traded in the US as American depositary receipts rose late Thursday morning, gaining 0.35% to 1,403.4 on the S&P Europe Select ADR Index. From continental Europe, the gainers were le
Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential'
Tesla CEO Elon Musk does not seem to agree with Republicans at least on one thing. On Wednesday, the billionaire, true to his credentials as a tech pioneer, unequivocally backed the mRNA technology, w
Deutsche Numis Reaffirms Their Hold Rating on BioNTech SE (BNTX)
In a report released today, Emmanuel Papadakis from Deutsche Numis maintained a Hold rating on BioNTech SE (BNTX), with a price target of $95.00.
HC Wainwright & Co. : The BioNTech (BNTX.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $107.00 to $113.00.
HC Wainwright & Co. : The BioNTech (BNTX.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $107.00 to $113.00.
HC Wainwright & Co. Maintains Buy on BioNTech, Raises Price Target to $113
HC Wainwright & Co. analyst Robert Burns maintains BioNTech (NASDAQ:BNTX) with a Buy and raises the price target from $107 to $113.
AstraZeneca Is Withdrawing COVID Shot Worldwide Due to Vaccine Glut
Buy Rating Affirmed for BioNTech Amid Strong Financials and Promising Oncology Pipeline
Cracking The Code: Understanding Analyst Reviews For BioNTech
Throughout the last three months, 12 analysts have evaluated BioNTech (NASDAQ:BNTX), offering a diverse set of opinions from bullish to bearish.
TD Cowen Adjusts BioNTech Price Target to $98 From $95, Maintains Hold Rating
TD Cowen Adjusts BioNTech Price Target to $98 From $95, Maintains Hold Rating.
Bank of Montreal, Canada: Maintaining the BioNTech (BNTX.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $123.00 to $122.00.
Bank of Montreal, Canada: Maintaining the BioNTech (BNTX.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $123.00 to $122.00.
BMO Capital Maintains Outperform on BioNTech, Lowers Price Target to $122
BMO Capital analyst Etzer Darout maintains BioNTech with a Outperform and lowers the price target from $123 to $122.
BioNTech Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/07/2024 33.42% BMO Capital $123 → $122 Maintains Outperform 04/17/2024 17.02% HC Wainwright & Co. → $10
BioNTech SE (NASDAQ:BNTX) Q1 2024 Earnings Call Transcript
Bank Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher Tuesday
Bank stocks helped European equities traded in the US as American depositary receipts higher late Tuesday morning, rising 0.77% to 1,396.19 on the S&P Europe Select ADR Index. From continental Europe,
Buy Rating for BioNTech SE on Strong H2 Revenue Outlook and Promising Oncology Pipeline
BioNTech: Hold Rating Maintained Amidst Lower Q1 Earnings and Steady Revenue Outlook
Analysis
Price Target
No Data
